Clinical Trials
9 trialsNCT04997902 2026-06-05
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
Phase 1/2 Completed
NCT03138070 2026-01-28
A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase NA Completed
NCT03601507 2024-04-17
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
University of Arizona
Phase 2 Terminated
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT02282371 2021-10-26
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02537223 2021-04-19
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
University Health Network, Toronto
Phase 1 Completed
NCT01602315 2020-12-29
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Novartis
Phase 1/2 Terminated
NCT02051751 2020-12-08
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Novartis
Phase 1 Completed
NCT02298595 2017-11-13
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
University of Pittsburgh
Phase 1/2 Withdrawn